Online inquiry

IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14505MR)

This product GTTS-WQ14505MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CNR1 gene. The antibody can be applied in Non-alcoholic fatty liver disease (NAFLD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001160226.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1268
UniProt ID P21554
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ14505MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15441MR IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA TSR-033
GTTS-WQ1725MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ADC-1013
GTTS-WQ1850MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AG1-25
GTTS-WQ13979MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ7452MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GBR-830
GTTS-WQ2180MR IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ALT-803
GTTS-WQ10981MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MCDS0593A
GTTS-WQ9513MR IVTScrip™ mRNA-Anti-EGFR, J2898A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA J2898A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW